Literatur
Europäische Kommission, www.ema.europa.eu/htms/human/referral/article31/methylphenidate.htm
Europäisches Parlament (2001) Richtlinie 2001/83/EG des europäischen Parlaments und des Rates vom 6. November 2001 zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel. Europäische Union, Straßburg, eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:de:PDF
Gould MS, Walsh BT, Munfakh JL et al (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001
Huss M, Hölling H, Kurth BM, Schlack R (2008) How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgement of health care professionals: results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry [Suppl 1] 17:52–58
Perrin JM, Friedman RA, Knilans TK, the Black Box Working Group and the Section on Cardiology and Cardiac Surgery (2008) Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122:451–453
Samuels JA, Franco K, Wan F, Sorof JM (2006) Effect of stimulants on 24-h blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 21:92–95
Schwabe U, Paffrath D (2008) Arzneiverordnungs-Report 2007. Springer, Berlin Heidelberg New York
Schwabe U, Paffrath D (2009)Arzneiverordnungs-Report 2009. Springer, Berlin Heidelberg New York
Stowe CD, Gardner SF, Gist CC et al (2002) 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 36:1142–1149
Vetter VL, Elia J, Erickson C et al (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs. A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young, Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117:2407–2423
Wernicke JF, Faries D, Girod D et al (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729–740
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Additional information
M. Hulpke-Wette und T. Paul für die Kommission für Arzneimittelsicherheit im Kindesalter (KASK) der DGKJ
Rights and permissions
About this article
Cite this article
Hulpke-Wette, M., Paul, T. Aufmerksamkeitsdefizit-Hyperaktivitäts-Störung. Monatsschr Kinderheilkd 158, 489–492 (2010). https://doi.org/10.1007/s00112-010-2219-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00112-010-2219-z